Modulation of Glucokinase Regulatory Protein: A Double-Edged Sword?

Research output: Contribution to journalArticleAcademicpeer-review

5 Citations (Scopus)

Abstract

The continuous search for drugs targeting type 2 diabetes mellitus (T2DM) has led to the identification of small molecules that disrupt the binding between glucokinase and glucokinase regulatory protein (GKRP). Although mice studies are encouraging, it will take years before these disruptors can be introduced to T2DM patients. Recently, genome-wide association studies (GWASs) have shown that variants in the gene encoding GKRP protect against T2DM and kidney disease but predispose to gout, nonalcoholic fatty liver disease, and dyslipidemia. These genetic data, together with previous experience with systemic and hepatospecific glucokinase activators, provide insight into the anticipated efficacy and safety of small-molecule disruptors in humans. Interestingly, they suggest that the opposite - enhanced GKRP-glucokinase binding - could be beneficial in selected patients.
Original languageEnglish
Pages (from-to)583-594
JournalTrends in Molecular Medicine
Volume21
Issue number10
DOIs
Publication statusPublished - 1 Jan 2015

Cite this

@article{a51410beb33d4a9cbe1a69a40a0dfecf,
title = "Modulation of Glucokinase Regulatory Protein: A Double-Edged Sword?",
abstract = "The continuous search for drugs targeting type 2 diabetes mellitus (T2DM) has led to the identification of small molecules that disrupt the binding between glucokinase and glucokinase regulatory protein (GKRP). Although mice studies are encouraging, it will take years before these disruptors can be introduced to T2DM patients. Recently, genome-wide association studies (GWASs) have shown that variants in the gene encoding GKRP protect against T2DM and kidney disease but predispose to gout, nonalcoholic fatty liver disease, and dyslipidemia. These genetic data, together with previous experience with systemic and hepatospecific glucokinase activators, provide insight into the anticipated efficacy and safety of small-molecule disruptors in humans. Interestingly, they suggest that the opposite - enhanced GKRP-glucokinase binding - could be beneficial in selected patients.",
author = "M.C.G.J. Brouwers and C. Jacobs and Aalt Bast and C.D.A. Stehouwer and N.C. Schaper",
year = "2015",
month = "1",
day = "1",
doi = "10.1016/j.molmed.2015.08.004",
language = "English",
volume = "21",
pages = "583--594",
journal = "Trends in Molecular Medicine",
issn = "1471-4914",
publisher = "Elsevier Limited",
number = "10",

}

Modulation of Glucokinase Regulatory Protein: A Double-Edged Sword? / Brouwers, M.C.G.J.; Jacobs, C.; Bast, Aalt; Stehouwer, C.D.A.; Schaper, N.C.

In: Trends in Molecular Medicine, Vol. 21, No. 10, 01.01.2015, p. 583-594.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Modulation of Glucokinase Regulatory Protein: A Double-Edged Sword?

AU - Brouwers, M.C.G.J.

AU - Jacobs, C.

AU - Bast, Aalt

AU - Stehouwer, C.D.A.

AU - Schaper, N.C.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - The continuous search for drugs targeting type 2 diabetes mellitus (T2DM) has led to the identification of small molecules that disrupt the binding between glucokinase and glucokinase regulatory protein (GKRP). Although mice studies are encouraging, it will take years before these disruptors can be introduced to T2DM patients. Recently, genome-wide association studies (GWASs) have shown that variants in the gene encoding GKRP protect against T2DM and kidney disease but predispose to gout, nonalcoholic fatty liver disease, and dyslipidemia. These genetic data, together with previous experience with systemic and hepatospecific glucokinase activators, provide insight into the anticipated efficacy and safety of small-molecule disruptors in humans. Interestingly, they suggest that the opposite - enhanced GKRP-glucokinase binding - could be beneficial in selected patients.

AB - The continuous search for drugs targeting type 2 diabetes mellitus (T2DM) has led to the identification of small molecules that disrupt the binding between glucokinase and glucokinase regulatory protein (GKRP). Although mice studies are encouraging, it will take years before these disruptors can be introduced to T2DM patients. Recently, genome-wide association studies (GWASs) have shown that variants in the gene encoding GKRP protect against T2DM and kidney disease but predispose to gout, nonalcoholic fatty liver disease, and dyslipidemia. These genetic data, together with previous experience with systemic and hepatospecific glucokinase activators, provide insight into the anticipated efficacy and safety of small-molecule disruptors in humans. Interestingly, they suggest that the opposite - enhanced GKRP-glucokinase binding - could be beneficial in selected patients.

U2 - 10.1016/j.molmed.2015.08.004

DO - 10.1016/j.molmed.2015.08.004

M3 - Article

VL - 21

SP - 583

EP - 594

JO - Trends in Molecular Medicine

JF - Trends in Molecular Medicine

SN - 1471-4914

IS - 10

ER -